Navigation Links
ESC announces review of Atrial Fibrillation Guidelines
Date:8/4/2011

The Guidelines Department of the European Society of Cardiology has issued the following statement today:

"The European Society of Cardiology (ESC) is aware of the early termination of the PALLAS trial (a randomised dronedarone versus placebo outcomes study in patients with permanent atrial fibrillation and cardiovascular risk) because of adverse outcomes associated with dronedarone.

Current ESC Guidelines for the Management of Atrial Fibrillation (AF) recommend the use of dronedarone in patients with atrial fibrillation as an antiarrhythmic agent, to prevent recurrence of the arrhythmia and to reduce the ventricular rate in patients with non-permanent atrial fibrillation (strictly in accordance with the indications approved by the European Medicines Agency) and to prevent cardiovascular hospital admissions (in line with the FDA approved indication, and consistent with the data included within the Summary of Product Characteristics approved by the EMA).

The European Guidelines strongly advise against administration of dronedarone to any patient with NYHA Class III or IV or recently unstable (decompensation within the last 4 weeks) heart failure.

Both the EMA and FDA have advised that the use of dronedarone should be restricted to the approved indications, and that dronedarone should not be used in patients with permanent atrial fibrillation. The ESC Guidelines are consistent with this advice.

Both agencies are presently reviewing the benefit-risk of dronedarone and will issue new regulations for dronedarone in due course. The ESC will produce a focused update of the AF Guidelines when the full results of PALLAS have been published and regulatory authorities have revised the labelling for dronedarone. The focused update of the AF Guidelines will also allow the incorporation of formal recommendations relating to the use of vernakalant, one or more of the new anticoagulant agents that are alternatives to warfarin, and left atrial appendage closure devices."

In a previous statement issued on 18 July 2011, the ESC had advised patients currently taking dronedarone not to stop their therapy and to consult their treating physician should they have any questions.


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-489-872-044
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
2. Connecture, Inc. Announces Partnership with MedicareCRM
3. Chiquita Announces Support for School Salad Bar Campaign
4. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
5. MDS Announces Agreements to Divest MDS Pharma Services Early Stage Business
6. MyDietShopz.com Announces Biggest Losers Contest - Share Your Story To Inspire Others
7. Rocketboy Media Wins Award for Masonic Lodge Web Site; Announces Signing of Several New Clients
8. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
9. Whitemark Homes Inc. Announces Change of Auditors and Additional Corporate Information
10. Sunquest Announces Major Software Updates and Enhancements
11. Data Strategy Announces SurePath Services Offering for EMC Avamar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , ... May 31, 2016 , ... According to recent ... States, and more than 100,000 physical therapy clinics. Each physical therapy professional and ... of clients. At the same time, staying afloat in a competitive industry is also ...
(Date:5/31/2016)... ... , ... Throughout the day, adults often find themselves reaching for a cup of coffee, an ... be reaching for instead is a cup of Matcha green tea. Matcha is a premium ... tea is harvested from early June to mid-July, when the leaves are the most tender. ...
(Date:5/31/2016)... ... , ... Twenty years ago it was revolutionary: enabling the people who hear ... they hear. But this approach has proven transformative, both for people who hear voices ... and now is used around the world, but it still lags in the United ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... device that enables unprecedented portability and convenience. , The Cube is exceptionally small—it ... in size, the Cube fits easily into any space, whether in a hospital, ...
(Date:5/31/2016)... ... May 31, 2016 , ... WaterField Designs, an innovative ... announces the waxed-canvas and leather Duo Dopp Kit , the ideal gift upgrade ... ballistic nylon, the Duo is smartly designed for Dad’s grooming routine. Two ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 2016 PaperHive Will Enable ... Elsevier,s ScienceDirect Database Elsevier , ... information products and services, today announced it will ... collaboration platform PaperHive to enable researchers to easily discover, ... on ScienceDirect , the world,s largest database ...
(Date:5/31/2016)... PUNE, India , May 31, 2016 ... 2016" market research report with comparative analysis of Asthma ... mechanism of action (MoA), route of administration (RoA) and ... and press releases. It also reviews key players involved ... on late-stage and discontinued projects. Complete report ...
(Date:5/30/2016)... , May 30, 2016 On ... eliminate viral hepatitis by 2030. At the 69 th ... ever Global Viral Hepatitis Strategy, signalling the greatest global commitment ... a goal of eliminating hepatitis B and C by 2030 ... if reached, will reduce annual deaths by 65% and increase ...
Breaking Medicine Technology: